Superpower Blood Test Review

Superpower sells an annual membership at $499 that covers two blood draws a year, each running 100+ biomarkers, delivered through a consumer mobile app. It sits in the same price band and the same product category as Function Health, and the base panels overlap substantially.

The company operates as a direct-to-consumer testing service rather than a medical practice. Blood work runs through accredited partner labs, orders are authorised through an affiliated clinician network where state law requires it, and the output is data plus written interpretation. Treatment is not part of the offering. This review covers how the process runs, what $499 buys and what it does not, what the panel reaches by body system, and where a twice-yearly snapshot stops being informative.

Public litigation

Superpower Health is the defendant in an open federal lawsuit brought by Function Health alleging false advertising and unfair competition under the Lanham Act (C.D. Cal., filed January 2026). These are allegations, not findings — Justia docket 2:26-cv-00810.

What Superpower is and how it works

The operational sequence is short and worth knowing before you pay, because two of the four steps have friction people do not anticipate.

1. Join and complete intake. Membership is purchased online and followed by a health questionnaire covering symptoms, history, and medications. This intake shapes which optional markers are suggested.
2. Book the draw. Draws happen at accredited partner lab locations. Mobile phlebotomy is available in supported markets but coverage is uneven — check your postcode before joining if an at-home draw is the reason you are interested.
3. Prepare correctly. Most of the panel wants an 8–12 hour overnight fast. Hormone markers, testosterone in particular, should be drawn in the morning because levels fall through the day. A draw booked for 4pm after lunch invalidates a meaningful share of what you paid for.
4. Read the results. Results typically land in the app in 7–14 days, presented marker by marker with plain-language explanations and flags against reference ranges. The second draw follows roughly six months later.

The full cost, including what is not included

The headline is $499 a year. The number that matters is $499 plus whatever you buy to make the results actionable.

Divided across 100+ markers and two draws, $499 is roughly $2.50 per biomarker per year — genuinely low against retail lab pricing, where a single advanced lipid panel ordered privately can run $100 or more on its own. The cost question is not whether the testing is well priced. It is whether an unaccompanied dataset changes anything you do.

Superpower at a glance

What the panel covers by system — and what it does not

A "100+ biomarker" count is a poor way to judge a panel, because counts inflate easily through related sub-markers. What matters is which systems get real coverage and which are absent entirely.

The absences are structural rather than oversights. Blood work cannot see plaque, so cardiovascular imaging is a separate purchase. It cannot see post-meal glucose behavior, so a CGM is a separate purchase. It cannot see a tumour, so whole-body imaging or a screening test is a separate purchase. A blood panel is one instrument, and knowing its edges prevents the most expensive mistake in this category: believing a clean panel means a clean bill of health.

What it measures versus what it interprets

Two different kinds of claim appear on the same screen with the same visual confidence, and they do not deserve equal weight.

• Measured. The lab values themselves — ApoB in mg/dL, HbA1c as a percentage, ferritin in ng/mL. These are real, standardised assays with known analytical variability, run at accredited labs.
• Interpreted. Whether a value is "optimal," what it implies about your risk, and what to do about it. Optimal ranges are narrower than standard lab reference ranges and vary by platform. A value flagged amber on one service can read as normal on another, from the same tube of blood. See normal versus optimal ranges for why that gap exists.

Biological variation compounds this. Many markers move 10–20% between draws for reasons that have nothing to do with health status: hydration, recent exercise, an infection two days ago, time of day, or a lab switching assay method. A single value crossing a threshold is weak evidence. The same direction of travel across two or three draws is much stronger, which is an argument for staying on a platform long enough to build a trend line rather than sampling once out of curiosity.

The limits of a twice-yearly snapshot

Two draws a year is a screening cadence, and it works well as one. It is a poor fit for anything you are actively changing. Start a statin and lipids respond within 6–8 weeks; wait six months for the recheck and you have spent half a year not knowing whether the dose is right. Begin iron repletion and ferritin needs 8–12 weeks to show movement. Adjust thyroid medication and TSH wants a recheck at six weeks. In each case the natural retest interval is shorter than the membership provides, so you pay for a targeted retest on top or you wait. Anyone in an active treatment phase should price that in.

Where Superpower differs

• App presentation. Results are built for a first-time reader, with guided explanations attached to each marker rather than a table of values.
• Onboarding. The intake questionnaire and setup walk someone through what the categories mean before any blood is drawn.
• Unbundled clinical layer. The consult sits outside the membership, which keeps the entry price at $499 for people who do not want one.
• Release cadence. Panels and app features have shipped at a fast pace, which means the offering you buy may differ from the one described in older write-ups.

Where Function Health differs

• Operating history. Function Health has run at consumer scale for longer, which means more accumulated user-side reporting on logistics and turnaround.
• Clinical review positioning. Result review by a clinician is presented as part of the membership structure rather than as a separate purchase.
• Results presentation. The interface leans closer to a clinical dashboard, which suits handing a printout to your own physician.
• Add-on catalogue. A somewhat wider set of advanced panels is available on top of the base membership.

Both lists have four entries by design. At $499 each, with overlapping panels and the same twice-yearly cadence, the choice between them turns on presentation and on whether you want the clinical layer bundled — not on a quality gap. The side-by-side comparison goes deeper.

The trade-offs, stated plainly

• Breadth versus depth. 100+ markers is wide coverage, and wide coverage produces incidental findings. Some flagged values will be benign variation, and chasing them costs money and worry. That is the cost of screening, not a defect in this platform.
• Low price versus unbundled care. $499 is inexpensive per marker precisely because clinical time is not in the price. Add two consults a year and the comparison set changes.
• Consumer app versus clinical record. An app built for readability is easier to use and slightly harder to hand to a physician than a conventional lab report. Export the PDF before an appointment.
• Fixed cadence versus your actual needs. Two draws a year is generous for stable screening and insufficient during any active treatment change.
• Newer platform versus track record. Fast feature development and a shorter operating history travel together. Both are real, and which one weighs more depends on your tolerance for a moving product.

Who Superpower fits, and who should choose something else

It fits a generally healthy adult who wants a wide baseline once or twice a year, is comfortable interpreting a dashboard, and has a primary care doctor or specialist to take flagged results to. It also fits someone who wants to establish a trend line across several years at a predictable annual cost.

Choose something else if:

• You want treatment, not just data. A physician-led program such as Lifeforce, Marek Health, or Opt Health — listed alphabetically — includes clinical decision-making and a scheduled reassessment cycle, from roughly $1,900 to $6,000 a year. That is a different purchase — care rather than screening — and the price reflects it.
• You want one test, not a membership. InsideTracker sells individual panels at $249–$589 covering roughly 48 biomarkers, with algorithmic food and training suggestions attached. Narrower coverage, no annual commitment.
• Hormones are the actual question. A general panel touches testosterone, SHBG, and estradiol but is not built around them. A hormone-focused service goes further on the markers that matter and attaches a prescriber. See TRT clinic options or hormone therapy for women.
• You have an active diagnosis being managed. Diabetes, thyroid disease, and cardiovascular disease under treatment need a testing rhythm set by a clinician, not a fixed six-month membership schedule.

How it compares

Six platforms that overlap with what Superpower does, including all three physician-led programs in this price range for contrast rather than any single one. Listed alphabetically; the order carries no ranking.

The spread across this table is roughly twenty-fold in price and the reason is not panel size. It is how much clinician time is included. Function Health, InsideTracker, and Superpower sit at one end with broad panels and minimal bundled clinical involvement; Lifeforce, Marek Health, and Opt Health sit at the other with smaller or self-configured panels and a prescriber attached. Decide which of those two groups you are buying first, then compare within it — cross-group price comparisons are comparing different products.

Related

• Full Superpower Health review
• Superpower cost breakdown
• Is Superpower worth it?
• Function Health vs Superpower
• Function Health alternatives
• Biomarker guides
• Doctor-led options, compared